EP2515872A1 - Forme d'administration orale contenant de l'entecavir - Google Patents
Forme d'administration orale contenant de l'entecavirInfo
- Publication number
- EP2515872A1 EP2515872A1 EP10798016A EP10798016A EP2515872A1 EP 2515872 A1 EP2515872 A1 EP 2515872A1 EP 10798016 A EP10798016 A EP 10798016A EP 10798016 A EP10798016 A EP 10798016A EP 2515872 A1 EP2515872 A1 EP 2515872A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- entecavir
- weight
- particle size
- value
- size distribution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229960000980 entecavir Drugs 0.000 title claims abstract description 85
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 title claims abstract 16
- 239000002245 particle Substances 0.000 claims abstract description 79
- 238000009826 distribution Methods 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 33
- 239000003381 stabilizer Substances 0.000 claims description 27
- 239000000945 filler Substances 0.000 claims description 25
- 239000006186 oral dosage form Substances 0.000 claims description 25
- 238000002156 mixing Methods 0.000 claims description 23
- 238000005469 granulation Methods 0.000 claims description 22
- 230000003179 granulation Effects 0.000 claims description 22
- 239000008187 granular material Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000000227 grinding Methods 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 12
- 239000007884 disintegrant Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 238000003801 milling Methods 0.000 claims description 9
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 7
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 claims description 4
- 239000000543 intermediate Substances 0.000 abstract description 99
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 208000002672 hepatitis B Diseases 0.000 abstract description 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- QDGZDCVAUDNJFG-FXQIFTODSA-N entecavir (anhydrous) Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 description 76
- 239000003826 tablet Substances 0.000 description 48
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 13
- 238000003825 pressing Methods 0.000 description 12
- 238000005550 wet granulation Methods 0.000 description 12
- 238000007908 dry granulation Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 10
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- 238000007906 compression Methods 0.000 description 9
- 230000006835 compression Effects 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001238 wet grinding Methods 0.000 description 5
- 229910002012 Aerosil® Inorganic materials 0.000 description 4
- 101710142246 External core antigen Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000004570 mortar (masonry) Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- -1 dextrates Substances 0.000 description 3
- VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000005096 rolling process Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 229920011250 Polypropylene Block Copolymer Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 229960005168 croscarmellose Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000009481 moist granulation Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MMIQPURTSGSCNM-UHFFFAOYSA-N (hydroxyamino)oxy-oxomethanesulfonic acid Chemical compound C(=O)(ONO)S(=O)(=O)O MMIQPURTSGSCNM-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- ZGXQVTHQPXDPGS-UHFFFAOYSA-N 2-[4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]purin-6-one Chemical compound C=C1C(CO)C(O)CC1C1=NC(=O)C2=NC=NC2=N1 ZGXQVTHQPXDPGS-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229940002637 baraclude Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950010614 entecavir monohydrate Drugs 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008023 pharmaceutical filler Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- Oral dosage form comprising entecavir
- the invention relates to pharmaceutical formulations, preferably in the form of an oral dosage form, for the treatment of chronic hepatitis B virus infections containing micronized entecavir, and to processes for their preparation.
- the invention further relates to intermediates containing micronized entecavir, in which the D50 value of the particle size distribution is less than 50 ⁇ m, and to processes for their preparation.
- Entecavir is a viral drug approved for the treatment of chronic hepatitis B virus infections. It belongs to the group of nucleoside reverse transcriptase inhibitors (NRTIs) and is a chemical analog of the nucleoside guanosine. Entecavir selectively inhibits HBV polymerase and thus DNA synthesis and replication of the hepatitis B virus in infected cells.
- NRTIs nucleoside reverse transcriptase inhibitors
- Hepatitis B viruses are viruses with cubic capsid symmetry that contain a circular double-stranded DNA. Their surface is formed by the hepatitis B surface antigen (HBsAg).
- the core contains the core antigen HBcAg and its cleavage product HBeAg, as well as a DNA polymerase and a phosphokinase.
- Free HBcAg is detectable only in liver cell nuclei.
- HBeAg is detectable in the acute stage of hepatitis and in some of the chronic virus carriers in the blood and is considered to be an important indicator of infectivity in addition to HBsAg.
- No HBeAg is formed in certain mutations of the core or precore gene, in which case the HBeAg determination leads to a false negative assessment of active virus multiplication in HBV infected individuals.
- entecavir The IUPAC name of entecavir is (1S, 3R, 4S) -2-amino-1,9-dihydro-9- [4-hydroxy-3-hydroxymethyl-2-methylenecyclopentyl] -6H-purin-6-one.
- the chemical structure of entecavir is shown in formula (1) below:
- Entecavir (1) The synthesis of entecavir has been described in WO 98/09964. Entecavir-containing pharmaceutical compositions are known from WO 2001/64221.
- Entecavir is marketed under the trade name Baraclude ® as a film tablet or oral solution.
- the active substance content of entecavir relative to the total weight of the film tablet is very low and is at the standard dosages of 0.5 and 1 mg entecavir, based on a total weight of the film tablet of greater than 200 mg less than 0.5 wt. %.
- This low level of active ingredient content can lead to significant salary uniformity issues during formulation production.
- small changes in the active ingredient content, caused by changes in flowability or segregation tendencies lead to deviations.
- the Ph. Eur. 6.0 Section 2.9.6 therefore requires a uniformity test of salary, where each individual salary of 10 units must be between 85 and 15 per cent of the average salary.
- An oral dosage form containing entecavir should be provided which should not cause an underdose or an overdose in the patient when properly used.
- an oral dosage form containing entecavir should be provided which ensures advantageous bioavailability in the patient.
- a further object of the present invention is to provide an oral dosage form containing entecavir whose active ingredient content, even after prolonged storage time, is within the concentration limits of 85 and 15% of the average content according to Ph. Eur.
- the tasks are also contrary to WO 200 1/06422 1 by means of little equipment, ie. H. for example by means of conventional mixing or granulation technology, be solvable.
- excipients (b) generally refers to one or more excipients.
- the invention therefore provides an intermediate comprising (a) entecavir and (b) auxiliaries, wherein the D50 value of the particle size distribution of the intermediate is less than 50 ⁇ m.
- Another object of the invention is an oral dosage form, preferably a solid oral dosage form containing the intermediate of the invention.
- Another object of the invention is a process for preparing an intermediate comprising (a) entecavir and (b) auxiliaries, wherein the D50 value of the particle size distribution of the intermediate is less than 50 ⁇ , comprising the steps:
- the invention further provides a process for the production of an oral dosage form comprising (a) entecavir and (b) auxiliaries, comprising the steps:
- Particle size distribution of the intermediate is less than 50 ⁇ ⁇ ,
- step (iii) filling the intermediate from step (iii) into dosage forms such as sachets or capsules,
- the invention further micronized entecavir.
- micronized entecavir for the treatment of chronic hepatitis B virus infections, in particular HBeAg-negative patients are treated.
- the term "entecavir” (1S, 3R, 4S) comprises -2-amino-1,9-dihydro-9 [4-hydroxy-3-hydroxymethyl-2-methylenecyclopentyl] -6H-purin-6-one according to the above formula (1)
- the term “entecavir” includes all pharmaceutically acceptable salts, hydrates and / or solvates thereof.
- the term “entecavir” is preferably entecavir in crystalline form, ie preferably more than 90% by weight of the entecavir used is present in crystalline form, in particular 100% by weight entecavir (a) is preferably used as the sole pharmaceutical active substance.
- the entecavir (a) used, or alternatively its pharmaceutically acceptable salt has a water content of from 0.01 to 10% by weight, more preferably from 4.0 to 8.0% by weight, more preferably from 5.0 to 7.0% by weight, more preferably from 5.5 to 6.5% by weight.
- the water content is preferably determined by the Karl Fischer method using a coulometer at 160 ° C. A Metrohm 831 KF Coulometer with a titration cell without a diaphragm is preferably used. Typically, a sample of 20 mg entecavir is analyzed.
- micronized entecavir is understood as meaning particulate entecavir having a particle size distribution D50 value of from 0.01 to 50 ⁇ m, preferably from 0.1 to 30 ⁇ m, more preferably from 1 to 20 ⁇ m, particularly preferably from 1.5 ⁇ m
- Micronized entecavir is usually obtainable by grinding, preferably in the following grinding devices: ball mill, air jet mill, pin mill, classifier mill, beater mill, disk mill, cutter mill, mortar mill, rotor mill, roll crusher, hammer mill , eg MicroCer from the company Netsch.
- Entecavir is usually used in amounts between 0.1 and 10 wt .-%, preferably between 0.15 and 5.0 wt .-%, particularly preferably between 0.2 and 2.0 wt .-%, based on the total weight of Intermediate according to the invention used.
- an intermediate in which the D 50 value of the particle size distribution of the intermediate is less than 50 ⁇ m. is.
- an intermediate is usually understood to mean a pharmaceutical composition which is not administered directly, but which is converted by suitable methods such as, for example, granulation and / or compression into an administrable oral administration form.
- particle size of a particle to be determined is understood as meaning the diameter of an equivalent particle, which is assumed to be spherical and has the same light scattering pattern as the particle to be determined
- a Mastersizer 2000 from Malvern Instruments is used.A wet measurement with a dispersion in dispersant, 2000 rpm, ultrasound 30 seconds is preferred. The evaluation is carried out for particles with a D50 value of less than 5.0 ⁇ m using the Mie method and for particles with a D50 value of 5.0 ⁇ or greater using the Fraunhofer method.
- particle size distribution of the intermediate is understood to mean the statistical distribution of the volume fractions in relation to all particle sizes of the particles of the intermediate According to the invention, the volume-related proportion is understood as a percentage of all particles having a defined particle size.
- the particle size distribution D50 value describes the particle size at which 50% by volume of the particles have a smaller particle size than the particle size which corresponds to the D50 value. Similarly, then 50% by volume of the particles have a larger particle size than the D50 value.
- the D90 value of the particle size distribution of the intermediate is defined as the particle size at which 90% by volume of the particles have a smaller particle size than the particle size corresponding to the D90 value.
- the D lO value of the particle size distribution of the intermediate is defined as the particle size at which 10% by volume of the particles have a smaller particle size than the particle size corresponding to the D lO value.
- the intermediate has a D50 value of the particle size distribution of 0.1 to 50 ⁇ m, preferably 0.1 to 30 ⁇ m, more preferably 1 to 20 ⁇ m, particularly preferably 1.5 to 15 ⁇ m and in particular 2 to 10 ⁇ m on.
- the intermediate usually has a D.sub.10 value of the particle size distribution between 4 and 12 .mu.m.sup.-2, preferably between 5 and 10 .mu.m.
- the intermediate has a D.sub.10 value between 0.05 and 5 .mu.m, preferably between 1.0 and 4.5 .mu.m.
- the expression between (for example) 4 and 12 ⁇ here is synonymous with the expression of 4 to 12 ⁇ .
- the intermediate usually has a D90 value of the particle size distribution of less than 250 / ⁇ m, preferably less than 200 ⁇ m, more preferably 10 to 180 ⁇ m, even more preferably 15 to 160 ⁇ m, in particular 20 to 120 ⁇ m.
- the ratio between the D90 value and D 10 value has a value between 5 and 20, preferably between 7 and 17.
- the ratio has a value between 1, 1 and 8.0, preferably between 1, 3 and 6.0, particularly preferably between 1, 5 and 5, 0, on.
- the particle size distribution of the intermediate according to the invention can be monomodal or bimodal. In a preferred embodiment of the invention, the particle size distribution of the intermediate is monomodal. In this context, "monomodal" is understood to mean that the particle size distribution has only one maximum in the representation in a histogram and / or a frequency distribution curve In the context of the invention, entecavir (a) forms an intermediate together with auxiliaries (b).
- adjuvants includes filler (b, surface stabilizer (b 2 ), disintegrant (b 3 ), flow control agent (b 4 ) and / or lubricant (b 5 )
- wetting agents (b 6 ) may also be used as adjuvants be used.
- fillers (b) are substances which are described in the prior art as pharmaceutical fillers These fillers are typically substances which are required to form the body of the oral dosage form in dosage forms with small amounts of active substance in order to obtain a sufficient amount to obtain Darreichungsmasse a suitable Darreichungsiere.
- fillers according to the invention for example, lactose, lactose derivatives, starch, starch derivatives, processed starch, chitin, cellulose and derivatives thereof, eg. microcrystalline cellulose (eg.
- Avicel ® sucrose, dextrates, dextrin Dextrose, maltodextrin, hydrogenated vegetable oil, kaolin, alkali or alkaline earth salts such as calcium phosphates, eg dicalcium hydrogen phosphate (for example in the form of the dihydrate or preferably of the anhydrate), calcium carbonate, magnesium carbonate, magnesium oxide, calcium sulfate, Sodium chloride, potassium chloride and mixtures thereof are used.
- Si0 2 modified microcrystalline cellulose e.g., B. Prosolv ®, Rettenmaier & Sohne, Germany
- B. Prosolv ® Rettenmaier & Sohne, Germany
- fillers are sugar alcohols and / or sugars (especially mono- and disaccharides) such as mannitol, sorbitol, xylitol, isomalt, glucose, fructose, maltose and mixtures thereof. In principle, it is also possible to use mixtures of the stated fillers.
- the fillers are preferably selected from mannitol, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, dicalcium hydrogen phosphate (preferably as anhydrate) and starch.
- Fillers (b 1) are usually used in amounts of between 10 and 99% by weight, preferably between 25 and 85% by weight, particularly preferably between 30 and 80% by weight, based on the total weight of the intermediate.
- the intermediate according to the invention preferably also contains surface stabilizers (b 2 ).
- surface stabilizers b 2
- Particles, especially of ground particles can prevent.
- the surface stabilizer is a polymer.
- the surface stabilizer also includes substances that behave polymer-like. Examples are fats and waxes. Of
- this includes low molecular weight oligomers, natural polymers or
- Emulsifiers Preferred surface stabilizers contain nonionic or ionic emulsifiers.
- the surface stabilizer (b 2 ) may be hydrophilic polymers. These are polymers which have hydrophilic groups. Examples of suitable hydrophilic groups are hydroxy, amino, carboxy, sulfonate.
- the hydrophilic polymer usable for the preparation of the intermediate preferably has a weight-average molecular weight of from 1,000 to 150,000 g / mol, more preferably from 2,000 to 90,000 g / mol. In the context of this application, the weight-average molecular weight is preferably determined by means of gel permeation chromatography.
- the resulting solution is preferred a viscosity of 0, 1 to 25 mPa 's, more preferably from 1, 0 to 18 Rapa-s, particularly from 2 to 15 mPa-s, measured at 25 ° C and in accordance with Ph. Eur., 6th edition, Chapter 2.2. 10, determined.
- the resulting solution preferably exhibits a viscosity of 2 to 10 mPa's.
- the intermediate of the present invention may include, for example, the following hydrophilic polymers as a surface stabilizer: polysaccharides such as hydroxypropylmethyl cellulose (HPMC), ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, ethyl hydroxyethyl cellulose, hydroxypropyl cellulose (HPC), salts of carboxymethyl cellulose; Polyvinylpyrrolidone, polyvinyl alcohol, polymers of acrylic acid and salts thereof, polyacrylamide, polymethacrylates, vinylpyrrolidone-vinyl acetate copolymers (e.g., Kollidon ® VA64, BASF), polyalkylene glycols and its derivatives such as polypropylene glycol or, preferably, polyethylene glycol, Polyethylensorbitan- fatty acid ester, co-block polymers of Polyethylene glycols, in particular co-block polymers of polyethylene glycol and polypropylene glycol (Pluronic ®
- Polyvinylpyrrolidone preferably having a weight-average molecular weight of 10,000 to 60,000 g / mol, in particular 12,000 to 40,000 g / mol, copolymer of vinylpyrrolidone and vinyl acetate, in particular having a weight-average molecular weight of 45,000 to 75,000 g / mol and / or is preferably used as the surface stabilizer Polymers of acrylic acid and salts thereof, in particular having a weight-average molecular weight of 50,000 to 250,000 g / mol used.
- HPMC in particular having a weight-average molecular weight of from 20,000 to 90,000 g / mol and / or preferably a proportion of methyl groups of from 10 to 35% and a proportion of hydroxyl groups of from 1 to 35%, is preferably used.
- HPC especially having a weight-average molecular weight of 50,000 to 100,000 g / mol, is preferably used.
- polyethylene glycol having a number-average molecular weight of from 2,000 to 40,000 g / mol, in particular from 3,500 to 25,000 g / mol.
- a polyethylene-polypropylene block copolymer is used, wherein the polyethylene content is preferably from 70 to 90% by weight.
- the polyethylene-polypropylene block copolymer preferably has a number-average molecular weight of from 1,000 to 30,000 g / mol, more preferably from 3,000 to 15,000 g / mol.
- surfactants can be used as surface stabilizers. Preference is given to using sodium lauryl sulfate (SDS).
- a combination of polymeric surface stabilizer and surfactant is used, e.g. a combination of HPMC and SDS.
- the weight ratio of polymeric surface stabilizer to surfactant is preferably 50: 1 to 3: 1.
- Auxiliaries in particular surface stabilizers and fillers
- plastic auxiliaries are distinguished by plastic deformation, while brittle auxiliaries under the action of a pressing force show a break of the particles into smaller particles.
- a brittle behavior of the surface stabilizer can be quantified by increasing the surface area in a compact. It is customary in the art to classify the brittleness by means of the so-called “yield pressure". According to a simple classification, the values for the "yield pressure" are small for plastic substances, but large for brittle substances [Duberg, M., Nyström, C, 1982, Studies on direct compression of tablets VI. Evaluation of methods for the estimation of particle fragmentation during compaction. Acta Pharm.
- the "yield pressure” describes the tension that must be achieved for the adjuvant (i.e., preferably the surface stabilizer and / or filler) to begin to flow plastically.
- the yield pressure will be determined from the reciprocal of the slope of the Heckel plot, as described in York, P., Drug Dev. Ind. Pharm., 18, 677 (1992), preferably at 25 ° C and a deformation rate of 0, 1 mm / s.
- an adjuvant in particular a surface stabilizer and / or filler
- a non-brittle adjuvant if it has a yield pressure of not more than 150 MPa, preferably from 5 to 80 MPa.
- a brittle excipient usually an excipient with a "yield pressure" of more than 80 MPa, preferably more than 150 MPa, referred to.
- Brittle auxiliaries can have a yield pressure of up to 500 MPa.
- non-brittle fillers examples are mannitol or starch.
- Non-brittle fillers are preferably used in the preparation of the intermediate according to the invention.
- examples of brittle fillers are microcrystalline cellulose or dicalcium hydrogen phosphate.
- Brittle auxiliaries, in particular brittle fillers are preferably added (in the granulation step (iii) and / or pressing step (iv) described below). In granulation step (iii) and / or pressing step (iv), non-brittle fillers or a mixture of brittle and non-brittle fillers may alternatively be added.
- non-brittle surface stabilizers examples include HPMC and polyvinylpyrrolidone, preferably with the abovementioned molecular weights.
- Surface stabilizers (b 2 ) are usually used in amounts of 1 to 30% by weight, preferably 2 to 20% by weight, particularly preferably 3 to 15% by weight, based on the total weight of the intermediate.
- disintegrant (b 3 ) substances that accelerate the disintegration of a dosage form, in particular a tablet after introduction into water.
- Suitable disintegrants are eg. organic disintegrants such as carrageenan, croscarmellose and / or crospovidone.
- alkaline disintegrants are meant disintegrating agents which when dissolved in water produce a pH of more than 7.0. Croscarmellose or crospovidone are preferred.
- Disintegrating agents are usually used in amounts of from 0 to 25% by weight, preferably from 0.1 to 20% by weight, particularly preferably from 3 to 15% by weight, based on the total weight of the intermediate.
- the intermediate according to the invention may additionally contain a flow-regulating agent (b 4 ).
- Flow regulators (b 4 ) have the task of reducing the interparticle friction (cohesion) between the individual particles as well as the adhesion of these to the wall surfaces of the mold (adhesion) in a tabletting mixture.
- An example of an additive to improve the powder flowability is dispersed silica (for example Aerosil ®). Preference is given to silica having a specific surface area of 50 to 400 m 2 / g, determined by gas adsorption according to Ph. Eur., 6th edition 2.9.26. , used.
- Flow regulators are usually used in amounts of 0 to 10% by weight, preferably 0 to 1 to 5% by weight, particularly preferably 1 to 3% by weight, based on the total weight of the intermediate.
- the intermediate may additionally contain lubricant (b 5 ).
- Lubricants (b 5 ) are generally used to reduce sliding friction.
- the sliding friction is to be reduced, which consists during tableting on the one hand between the up in the die bore and moving down punches and the die wall and on the other hand between the tablet web and die wall.
- Suitable lubricants provide eg. Stearic acid, adipic acid, sodium stearyl fumarate (Pruv ®), magnesium stearate and / or calcium stearate is.
- Lubricants (b 5 ) are customary in amounts of from 0 to 5% by weight, preferably from 0.1 to 2% by weight, particularly preferably from 0.5 to 1.5% by weight, based on the total weight of the intermediate , used.
- the intermediate according to the invention may contain the above-described components (a) and (b) to (b 5 ) However, it is also possible in the preparation of oral administration forms that the constituents (b 1, (b 3 ), (b 4 ) and (b 5 ) (at least partially) are added only before or during the (subsequently described) granulation and / or pressing step.
- the intermediate according to the invention contains
- fillers between 5 and 90% by weight, preferably between 25 and 85% by weight, particularly preferably between 30 and 80% by weight,
- (b 2 ) surface stabilizer between 1 to 30% by weight, preferably 2 to 20% by weight, particularly preferably 3 to 15% by weight
- (b 3 ) disintegrant between 0 to 40% by weight, preferably 1, 0 to 20% by weight, particularly preferably 2, 0 to 15% by weight.
- the intermediate of the invention may also consist of the abovementioned components (a) and (b ⁇ to (b 3 ).
- total weight of the intermediate refers to the weight of the active ingredients and adjuvants contained in the intermediate. That is, it refers to the weight of the intermediate without solvent (used, for example, in the wet grinding method described below).
- Another object of the present invention is an oral dosage form containing the intermediate of the invention.
- oral dosage form in the context of the invention is meant a drug formulation that is administered orally.
- Oral dosage forms in the context of this invention are preferably tablets or capsules.
- packaging such as sachets or stickpacks which contain the intermediate according to the invention (if appropriate in granulated form) can also be regarded as oral administration forms.
- the oral dosage form according to the invention contains a substantial proportion of the intermediate according to the invention.
- the oral dosage form according to the invention preferably contains more than 2 to 100% by weight of intermediate according to the invention, more preferably 5 to 80% by weight of intermediate according to the invention, even more preferably 10 to 50% by weight of intermediate according to the invention, particularly preferably 15 to 40% by weight. %, in particular 20 to 35% by weight of intermediate according to the invention. This is based on the total weight of the active ingredients and excipients of the oral dosage form. That is, e.g. in the case of capsules, sachets or stickpacks, the empty weight of the capsules, sachets or stickpacks is not taken into account.
- Another object of the invention relates to a process for the preparation of the intermediate according to the invention.
- the preparation according to the invention comprises the steps
- step (i) (a) admecavir and excipients (b) are mixed.
- mixing in the sense of the invention is meant a substance combining process with the aim of substantially homogenous distribution of various substances by the action of mechanical forces.Mixing in the sense of the invention takes place in conventional mixing devices such as, for example, rolling mats, shaking mixers, free-fall mixers, shear mixers, plowshare mixers, planetary mixers. Mixing kneader, Z or Sigma kneader or fluid or intensive mixer A free-fall mixer is preferably used.
- the mixing time is usually 0, 5 minutes to 1 hour, preferably 2 minutes to 50 minutes, more preferably 5 minutes to 30 minutes.
- step (ii) (a) entecavir and excipients (b) are ground.
- grinding is understood as meaning the comminution of substances, in particular of active ingredients and auxiliaries, to a predetermined particle size spectrum by the application of external force
- the comminution principle can usually include pressure, friction, cutting, impact, impact or combinations thereof
- wet milling is the comminuting of solids in the liquid phase, the liquid phase preferably being a liquid in which entecavir and auxiliaries are present
- suitable grinding fluids are methanol, ethanol, isopropanol, acetone, chloroform, butanol, ethyl acetate, heptane, pentanol or mixtures thereof
- Acetone is preferably used n Grinders, for example in a ball mill, air jet mill, pin mill, classifier mill, beater mill, disk mill, cutting mill, mortar mill, rotor mill, a roll crusher, a hammer mill.
- the intermediate is prepared by wet milling and subsequent drying.
- the mixing and milling conditions are chosen so that an intermediate having the above-described particle size distribution (DIO, D50, D90, D90 / D50, D50 / D10, D90 / D10) is obtained.
- the grinding temperature should be less than 220 ° C, preferably - 1 78 ° C to 180 ° C.
- the mixing and milling conditions are preferably selected such that an intermediate having a uniformity of the mixture of from 90% to 110%, more preferably 92% to 108%, even more preferably 94% to 106%, most preferably 96% to 104 % and especially 98% to 102%.
- the "uniformity of the mixture” here refers to the uniformity of the active ingredient content in different intermediate samples. To determine the uniformity of the mixture, for blends of less than 10 kg, five incremental samples are taken randomly from the intermediate. For mixtures with a mass of 10 kg or more, ten individual samples are taken. The uniformity of the drug content is then determined according to Ph. Eur. 6.0, chapter 2.9.6, using HPLC as the analytical method.
- the invention thus also relates to an entecavir-containing intermediate in particulate form with a uniformity of the mixture of 90% to 1 10%, more preferably 92% to 108%, even more preferably 94% to 106%, particularly preferably 96% to 104 % and in particular 98% to 102%.
- steps (i) and (ii) can be carried out one behind the other and / or simultaneously in the process according to the invention. The steps may also be repeated if necessary. For example, a cycle comprising mixing, grinding, mixing possible.
- steps (i) and (ii) follow the trituration method.
- entecavir (a) is first mixed with a part (preferably with 10 to 50% by weight, particularly preferably 15 to 40% by weight) of the amount of excipient and ground and then, with grinding, a further addition of the remaining amount of excipient takes place.
- the addition of the remaining amount of excipient is preferably carried out in one to 5 steps, in particular in 2 to 4 steps.
- the invention relates to a process for the preparation of the oral dosage form, preferably a solid oral dosage form, which contains the abovementioned intermediate.
- the invention thus relates to a method comprising the steps (i) mixing (a) entecavir and (b) excipients, and
- step (ii) or (iii) in dosage forms such as sachets or capsules, wherein before or during the steps (iii) and (iv) optionally further pharmaceutical excipients may be added.
- step (i) (a) admecavir and excipients (b) are mixed.
- admecavir and excipients (b) are mixed.
- step (ii) (a) entecavir and excipients (b) are ground to produce an intermediate.
- steps (i) and (ii) can be combined as desired, as explained above.
- auxiliaries added before or during the granulation and / or pressing step likewise to have the D 10, D 50 and D 90 values of the particle size distribution explained above for the intermediate.
- the auxiliaries added before or during the granulation and / or pressing step have a larger particle size (D50) than the intermediate, eg. B. a D50 value of 55 to 180 ⁇ .
- the adjuvants optionally added during the granulating and / or pressing step have the following particle size (D50):
- D50 particle size
- Embodiment 1 Direct compression into tablets
- Embodiment 2 Dry granulation and subsequent compression into tablets
- Embodiment 3 wet granulation and subsequent compression into tablets
- Embodiment 4 Dry granulation and subsequent filling in administration forms such as sachets, stickpacks or capsules;
- Embodiment 5 Wet granulation and subsequent filling in dosage forms such as sachets, stickpacks or capsules;
- Embodiment 6 Spray-drying and subsequent filling in dosage forms such as sachets, stickpacks or capsules;
- Embodiment 7 Spray-drying and subsequent compression into tablets
- Embodiment 8 Lyophilization and subsequent filling in dosage forms such as sachets, stickpacks or capsules;
- Embodiment 9 Lyophilization and subsequent compression into tablets.
- Embodiment 1 does not require a granulation step (iii), but embodiments 2 to 5 already require. In optional step (iii), the intermediate is thus granulated.
- Gramulating generally means the formation of coarser or granular aggregates than powder by aggregation and / or aggregation of finer powder particles (build-up granulation) and / or the formation of finer granules by fragmentation of coarser aggregates (degradation granulation) dry granulation means.
- the dry granulation is generally carried out by application of pressure or temperature.
- the wet granulation is generally performed by use of surface stabilizers (b 2) and / or solvents.
- the granulation is generally carried out in conventional granulating apparatus, such as extruder, perforated-disk mill, Pipe roll or fluidized bed granulators Also compulsory mixers or spray dryers may be used
- the particle size distribution of granules is usually used Excipients (b)) determined by sieve analysis. This is done for 10 minutes using suitable sieves according to Ph. Eur 6.0 2.9. 12. sieved, preferably with a Retsch ® AS 200. Accordingly, the D50 value of the granule particle size distribution describes the particle size at which 50% by weight of the particles have a smaller particle size than the particle size corresponding to the D50 value.
- the granulation time is, in particular in the case of wet granulation, usually 1 minute to 1 hour, preferably 2 minutes to 30 minutes. Dry granulation is usually carried out as a continuous process. Preferred embodiments of dry and wet granulation will be explained below.
- Dry granulation Usually, dry granulation is preferred when grinding the intermediate in the dry state.
- step (iii) of the process according to the invention the intermediate according to the invention from step (ii) is compacted into a rag.
- the Kompaktianssbedlteilungen in step (iii) are preferably selected so that the Schülpe a density of 1, 03 to 1, 8 g / cm 3 , in particular from 1, 05 to 1, 7 g / cm 3 .
- the compaction is preferably carried out in a roll granulator.
- the rolling force is preferably 2 to 50 kN / cm, more preferably 4 to 30 kN / cm, in particular 10 to 25 kN / cm.
- the gap width of the rolling granulator is for example 0, 8 to 5 mm, preferably 1 to 4 mm, more preferably 1, 5 to 3 mm, in particular 1, 8 to 2, 8 mm.
- the slug is preferably granulated.
- the granulation can be carried out by methods known in the art.
- the dry granulation conditions are selected such that the resulting granules have a D50 of 55 to 600 ⁇ , more preferably 70 to 450 / im, more preferably 100 to 400 ⁇ , in particular from 1 50 to 350 / ⁇ m.
- the granulation of the slug is carried out in a sieve mill.
- the mesh size of the sieve insert is usually 0, 1 to 5 mm, preferably 0, 4 to 3 mm, more preferably 0, 61 to 2 mm, in particular 0, 7 to 1, 8 mm.
- the intermediate according to the invention is used for the dry granulation process.
- smaller amounts of pharmaceutical excipients may be added which are not present in the particle size distribution according to the invention.
- fluxing agents 90 to 100% by weight, more preferably 95 to 99.9% by weight, of intermediate according to the invention are preferably used in the dry granulation step, based on the total weight of the substances used.
- a wet granulation can be done by conventional methods. Wet granulation is preferred if the preparation of the intermediate according to the invention was carried out by wet grinding. Preferably, a wet granulation takes place in the fluidized bed.
- the intermediate from step (ii), preferably the moist intermediate from step (ii), is introduced into a fluidized bed.
- carrier cores can be initially introduced in the fluidized bed.
- the aforementioned fillers are possible. Preference is given to using microcrystalline cellulose.
- the carrier cores usually have a particle size (D50 value) of 55 to 500 / im, more preferably from 60 to 350 ⁇ , even more preferably 90 to 250 ⁇ , in particular from 1 10 to 220 ⁇ .
- the weight ratio of intermediate according to the invention to carrier cores is preferably 10: 1 to 1: 2, more preferably 5: 1 to 2: 1. The weight ratio indicated here preferably refers to the dry intermediate.
- the intermediate according to the invention for the wet granulation method, essentially only the intermediate according to the invention and optionally the carrier cores explained above are used. Optionally, but not preferred, can smaller amounts of other pharmaceutical excipients are added.
- the wet granulation is performed in a fluidized bed, for example, in a Glatt GPCG ® 3 (Glatt GmbH, Germany).
- a step of "drying" is usually applied, and the drying step may be performed after or simultaneously with the granulation step.
- drying is the separation of liquids adhering to solids.
- the adhering liquids are preferably water in the form of adhesive water, capillary, hydration, adsorption, hydrate and constitution water
- the drying and granulation process is preferably carried out in one apparatus, preferably the drying conditions are selected such that the water content of the resulting granules is 0.1 to 5% by weight.
- the content of residual solvent is preferably 1 to 1000 ppm, preferably 5 to 500 ppm
- the moist granulation conditions are selected so that the resulting particles (granules) have a particle size (D50 value) of 55 to 600 ⁇ ., More preferably from 70 to 450 ⁇ , more preferably 100 to 400 ⁇ , in particular from 150 to 350 im.
- the granulation conditions are preferably selected such that the resulting granules have a bulk density of 0.2 to 0.85 g / ml, more preferably 0.3 to 0.8 g / ml, in particular 0 to 4 to 0, 7 g / ml.
- the Hausner factor is usually in the range of 1, 03 to 1, 3, more preferably from 1, 04 to 1, 20 and in particular from 1, 04 to 1, 15.
- the "Hausner factor" Ratio of tamped density to bulk density understood. Bulk density and tamped density are determined according to USP 24, Test 616 "Bulk Density and Tapped Density". Further, the mixing, milling and / or granulating conditions are preferably selected such that granules having a uniformity of the mixture of from 90% to 110%, more preferably 92% to 108%, even more preferably 94% to 106%, especially preferably 96% to 104% and in particular 98% to 102% is obtained.
- the "uniformity of the mixture” here refers to the uniformity of the active ingredient content in different granule samples. To determine the uniformity of the mixture of granules having a mass of less than 10 kg, five individual samples are taken randomly from the granules and the uniformity of the active ingredient content is determined as explained above. For granulate mixtures with a mass of 10 kg or more, ten individual samples are taken.
- the invention also relates to granules obtainable by a process comprising the steps
- the invention also relates to an entecavir-containing granules having a uniformity of the mixture of 90% to 110%, more preferably 92% to 108%, even more preferably 94% to 106%, particularly preferably 96% to 104% and in particular 98% to 102%.
- the granulate according to the invention can be filled for use as an oral dosage form, for example in capsules, stick packs or sachets.
- the intermediate from step (ii) or the granulated intermediate from step (iii) is compressed into tablets.
- Direct compression is preferred.
- the pressing step essentially only the intermediate according to the invention - if appropriate as described above in granulated form - is used.
- smaller amounts of pharmaceutical excipients may be added which are not present in the particle size distribution according to the invention.
- Examples include fluxing agents, disintegrants and lubricants. 60 to 100% by weight, more preferably 70 to 99.9% by weight of intermediate according to the invention or 80 to 100% by weight, more preferably 85 to 99.9% by weight, of granules resulting from the method step are preferred in the pressing step (iii), based on the total weight of the compressed substances.
- the tableting conditions are preferably selected so that the resulting tablets have a tablet height to weight ratio of 0.005 to 0.3 mm / mg, more preferably 0.05 to 0.2 mm / mg.
- Tablettiermaschinen the tabletting machines customary for tablet production can be used. Preference is given to using a rotary press or eccentric press. In the case of concentric presses, a pressing force of 2 to 40 kN, preferably of 2, 5 to 35 kN is usually used. In the case of eccentric presses usually a pressing force of 1 to 20 kN, preferably from 2, 5 to 10 kN applied. For example, the Korsch ® EK0 is used.
- the resulting tablets preferably have a mass of 100 to 550 mg, preferably 150 to 450 mg, particularly preferably 180 to 420 mg, based on the total weight of the unformed tablet.
- the resulting tablets have a mass of from 350 to 450 mg, more preferably from 370 to 430 mg per mg of entecavir.
- the oral dosage form according to the invention in particular the tablet according to the invention,
- (b t ) fillers between 30 and 99, 8% by weight, preferably between 55 and 98% by weight, particularly preferably between 75 and 95% by weight,
- (b 2 ) surface stabilizer between 0.1 to 30% by weight, preferably 0.5 to 15% by weight, particularly preferably 1.0 to 10% by weight
- (b 3 ) disintegrant between 0 and 30% by weight, preferably 1, 0 to 20% by weight, particularly preferably 3, 0 to 15% by weight
- (b 4 ) flow control agent between 0 to 10 wt.%, preferably 0, 1 to 6, 0 wt.%, particularly preferably 0.8 to 4, 0 wt.%,
- Lubricant between 0 and 10% by weight, preferably 0, 1 to 5% by weight, particularly preferably 0, 5 to 3, 0% by weight, based on the total weight of the unformed tablet.
- the resulting tablets may be coated or uncoated.
- Cellulose derivatives MC
- EC ethylcellulose
- HEC hydroxyethylcellulose
- methacrylic acid-acrylate copolymers such as methacrylic acid-ethacrylate copolymer or methacrylic acid-methyl methacrylate copolymer
- vinyl polymers such as polyvinylpyrrolidone or Polyvinyl acetate phthalate
- natural film formers such as shellac
- the layer thickness of the coating is usually 0, 1 to 100 / im, preferably 1 to 80 / im.
- the optionally applied film has substantially no effect on the release.
- they are preferably films without influence on the drug release.
- neither enteric film coatings nor delayed-release coatings are preferably used.
- the resulting tablets should preferably have a high hardness and a low friability.
- the resulting tablets preferably have a hardness of from 50 to 300 N, more preferably from 80 to 250 N, in particular from 100 to 220 N. Hardness is calculated according to Ph.Eur. 6.0, section 2.9.8.
- the resulting tablets usually have a friability of 0, 1 to 0, 8%, preferably 0, 2 to 0.6 and particularly preferably 0.3 to 0.5%.
- the friability is calculated according to Ph.Eur. 6.0, Section 2.9.7.
- the release profile of the tablets according to the invention has, according to USP method (paddle, 900 ml of test medium in phosphate buffer at pH 6.8 and 37 ° C, 75 rpm) after 10 minutes usually has a released content of at least 30%, preferably at least 50%, in particular at least 70%.
- the intermediate from step (ii) or the granules from step (iii) are filled into dosage forms such as sachets, stickpacks or capsules.
- Example 1 Four different intermediates according to the invention containing entecavir (Examples 1 to 4) and a conventional powder mixture comprising entecavir (Comparative Example 1) were prepared. In addition, four tablets of the present invention containing entecavir of Examples 1 to 4 and conventional tablets containing entecavir of Comparative Example 1 were prepared.
- Entecavir was triturated with 15 mg of mannitol in a mortar for 5 min. Then HPMC was added and ground for a further 5 min. In two further steps, half of the remaining mannitol was added with 5 minutes grinding.
- the resulting intermediate was treated with MCC, Natrlumcarboxymethylcellulose and Aerosil ® for 20 minutes in free fall mixer (Turbula ® TB 10) were mixed and magnesium stearate through a 0.5 mm sieve was added and the final mixture for another 3 min mixed.
- the prepared mixture was compressed on a Korsch eccentric press into tablets.
- Entecavir was triturated with 15 mg of corn starch in a mortar for 5 min. Then HPMC was added and ground for a further 5 min. In two further steps, half of the remaining cornstarch was added with a 5-minute grind.
- Entecavir and lactose monohydrate were in micronized form (D50 ⁇ 50 ⁇ ) before. Both substances were mixed gradually.
- Entecavir was milled together with HPMC and SDS in acetone for 1 h in a Netzsch® MicroCer.
- the ground suspension which contained the intermediate according to the invention, was spray-dried on a Büchi® spray tower with the addition of microcrystalline cellulose (D50 of about 100 ⁇ m). Tablet :
- the mixture consisting of MCC and intermediate was mixed after spray-drying together with the remaining excipients, with the exception of magnesium stearate, for 25 min on a free-fall mixer (Turbula® TB 10). Subsequently, 2 mg of magnesium stearate was added via a 0.5 mm sieve and mixed again for 3 min. The resulting mixture was compressed on a Korsch eccentric press into tablets.
- Example 2 The same recipe as in Example 1 was used. As excipients and active ingredient (entecavir) were non-micronized, used commercially available products, without milling: entecavir was added together with 1 5 mg mannitol for 5 min mixed in the free fall mixer (Turbula ® TB 10). Then HPMC was added and mixed for a further 5 minutes. In two further steps, half of the remaining mannitol was added with mixing for 5 minutes. The D50 value of the particle size distribution of the powder mixture was outside the range claimed according to the invention.
- the resulting mixture was mixed with MCC, sodium carboxymethylcellulose and Aerosil® for 20 minutes in the tumbler (Turbula® TB 10) and magnesium stearate added via a 0.5 mm sieve and the final mixture mixed for an additional 3 minutes.
- the content of entecavir of the tablets prepared according to Examples 1 to 4 showed a uniformity of the content of each of 10 units between 91% and 109% of the average content.
- the tablets according to the invention prepared according to Examples l b to 3b therefore corresponded to the test for uniformity of the content.
- the tablets prepared according to Comparative Example 1 showed a uniformity of the content of 9 units between 86% and 13%.
- One tablet was found to contain 1 17% of the average content, and 20 more tablets were tested for salary uniformity according to Ph. Eur. 6.0 Section 2.9.6.
- Twenty-nine of the 30 tablets tested had a content within the limits of 85% and 15% of the average content of the 30 tablets.
- the content of a tablet had a content within the limits of 75% and 125%.
- the tablets prepared according to the comparative examples therefore corresponded to the check for uniformity of the content.
- the tablets prepared according to Examples 1 to 4 showed a sufficiently high bioavailability and no signs of intoxication occurring.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE200910060194 DE102009060194A1 (de) | 2009-12-23 | 2009-12-23 | Orale Darreichungsform umfassend Entecavir |
DE102010048635 | 2010-10-15 | ||
PCT/EP2010/007892 WO2011076412A1 (fr) | 2009-12-23 | 2010-12-22 | Forme d'administration orale contenant de l'entecavir |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2515872A1 true EP2515872A1 (fr) | 2012-10-31 |
Family
ID=43629662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10798016A Withdrawn EP2515872A1 (fr) | 2009-12-23 | 2010-12-22 | Forme d'administration orale contenant de l'entecavir |
Country Status (4)
Country | Link |
---|---|
US (1) | US20120308652A1 (fr) |
EP (1) | EP2515872A1 (fr) |
EA (1) | EA201290556A1 (fr) |
WO (1) | WO2011076412A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013114389A1 (fr) * | 2011-12-21 | 2013-08-08 | Mylan Laboratories Limited. | Procédé de préparation de formulations solides à administrer par voie orale comprenant une faible dose d'entécavir |
EP2644197A1 (fr) * | 2012-03-26 | 2013-10-02 | Sanovel Ilac Sanayi ve Ticaret A.S. | Nouvelles compositions pharmaceutiques d'entécavir |
EP2644196B1 (fr) * | 2012-03-26 | 2019-09-18 | Arven Ilac Sanayi ve Ticaret A.S. | Compositions pharmaceutiques d'entecavir |
KR101285008B1 (ko) * | 2012-04-18 | 2013-07-10 | 제일약품주식회사 | 저용량 엔테카비어의 경구투여 제제의 제조방법 |
CN102652737A (zh) * | 2012-04-21 | 2012-09-05 | 浙江华海药业股份有限公司 | 恩替卡韦片及其制备方法 |
CA2779052A1 (fr) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Composition pharmaceutique d'antecavir et processus de fabrication |
CN103908436B (zh) * | 2012-12-29 | 2016-02-10 | 安徽贝克生物制药有限公司 | 一种速释型恩替卡韦组合物 |
CN108785273B (zh) * | 2018-09-18 | 2021-01-01 | 四川海思科制药有限公司 | 一种恩替卡韦胶囊药物组合物及其制备方法 |
CN112370434B (zh) * | 2020-10-26 | 2022-10-21 | 石药集团欧意药业有限公司 | 一种恩替卡韦片剂组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008098471A1 (fr) | 2007-02-14 | 2008-08-21 | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory | Forme cristalline d''entecavir, son mode de préparation, compositions pharmaceutiques et utilisations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998009964A1 (fr) | 1996-09-03 | 1998-03-12 | Bristol-Myers Squibb Company | PROCEDE DE PREPARATION AMELIORE DE L'AGENT ANTIVIRAL [1S-(1α, 3α, 4β)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENE-CYCLOPENTYL]-6-H-PURINE-6-ONE |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
ATE312613T1 (de) * | 2000-02-29 | 2005-12-15 | Bristol Myers Squibb Co | Niedrig dosierte entecavir formulierung und deren verwendung |
US7445796B2 (en) * | 2002-08-19 | 2008-11-04 | L. Perrigo Company | Pharmaceutically active particles of a monomodal particle size distribution and method |
US20090227637A1 (en) * | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
-
2010
- 2010-12-22 WO PCT/EP2010/007892 patent/WO2011076412A1/fr active Application Filing
- 2010-12-22 EP EP10798016A patent/EP2515872A1/fr not_active Withdrawn
- 2010-12-22 US US13/517,981 patent/US20120308652A1/en not_active Abandoned
- 2010-12-22 EA EA201290556A patent/EA201290556A1/ru unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008098471A1 (fr) | 2007-02-14 | 2008-08-21 | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory | Forme cristalline d''entecavir, son mode de préparation, compositions pharmaceutiques et utilisations |
Non-Patent Citations (5)
Also Published As
Publication number | Publication date |
---|---|
US20120308652A1 (en) | 2012-12-06 |
WO2011076412A1 (fr) | 2011-06-30 |
EA201290556A1 (ru) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2515872A1 (fr) | Forme d'administration orale contenant de l'entecavir | |
EP2364141B1 (fr) | Moxifloxacine compactée | |
US20130095177A1 (en) | Method of preparing an oral dosage form comprising fingolimod | |
DE20220415U1 (de) | Tamsulosin-Tabletten | |
WO2010054833A1 (fr) | Produits intermédiaires et formes galéniques orales contenant de la lénalidomide | |
EP2309995A1 (fr) | Formulation pharmaceutique pour la réduction de la pression artérielle pulmonaire | |
WO2012010669A2 (fr) | Médicament d'administration orale contenant un mélange de silodosine et d'un copolymère basique | |
WO2010017918A2 (fr) | Ambrisentan amorphe | |
EP2413910A1 (fr) | Comprimés contenant de la dapoxétine et procédé de traitement à sec pour leur préparation | |
WO2011047837A2 (fr) | Cinacalcet granulé par fusion | |
EP2515852B1 (fr) | Comprimé orodispersible contenant une base de sildenafil compactée | |
EP2408424A2 (fr) | Transformation à sec de rétigabine | |
EP2566461A2 (fr) | Tapentadol solide sous forme non cristalline | |
WO2017045743A1 (fr) | Comprimés à libération des principes actifs indépendante des substances de libération | |
EP2445484A1 (fr) | Aprépitant sous forme de solution solide | |
DE102009060194A1 (de) | Orale Darreichungsform umfassend Entecavir | |
WO2010004022A1 (fr) | Comprimés d'aliskirène fabriqués par compression directe | |
WO2010101485A2 (fr) | Composition pharmaceutique contenant du célécoxib et son procédé de fabrication | |
DE102006006588A1 (de) | Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung | |
WO2012016708A1 (fr) | Forme pharmaceutique orale comportant la diméboline et le donézépil | |
EP2382967A1 (fr) | Aliskiren sous forme d'une dispersion solide | |
EP1682086A2 (fr) | Formulation de medicament contenant un antagoniste de ltb sb 4 /sb , et procedes de production et utilisation de cette formulation de medicament | |
DE102008057285A1 (de) | 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung | |
DE102008057335A1 (de) | Amorphes Lenalidomid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
17P | Request for examination filed |
Effective date: 20120706 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20130410 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RATIOPHARM GMBH |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170221 |